Stay updated on Nivolumab in AML Remission at High Risk Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.

Latest updates to the Nivolumab in AML Remission at High Risk Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check10 days agoChange DetectedDifference0.6%
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedDifference0.9%
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.8%
- Check38 days agoChange DetectedDifference1.0%
- Check45 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new study identifiers and collaborators, while removing detailed descriptions of a clinical trial involving nivolumab for acute myeloid leukemia. The revision number has also been updated.SummaryDifference41%
Stay in the know with updates to Nivolumab in AML Remission at High Risk Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.